Navigation Links
Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up

PORTOLA VALLEY, Calif., July 31, 2014 /PRNewswire/ -- Rogne Bioscience, a privately-held biotechnology company based in San Francisco Bay Area, has acquired a licence to anti-inflammatory peptides from Isis Innovation, the University of Oxford's commercialisation company. The potent anti-inflammatory activity of the peptides was discovered by Professor David Greaves at the University of Oxford's Sir William Dunn School of Pathology.

The company, which has raised over $1.5 million in seed financing, is developing a first-in-class, topical biologic to address the unmet need for a safe, effective, non-steroidal treatment for patients with mild to moderate psoriasis.

Tom Gadek, CEO of Rogne, said: "In Rogne's feasibility studies, we have been able to verify the anti-inflammatory activity of the peptide that was first published by Professor Greaves' lab. We have also demonstrated that the peptide can be formulated to penetrate human skin and, when applied topically, inhibits dermal inflammation in a dose-dependent manner in mice. We plan to complete a clinical proof of concept study to demonstrate activity in psoriasis patients."

Professor Greaves said: "Because the peptide will be applied to the skin, we expect to avoid the side-effects which trouble patients who use current injected or oral psoriasis drugs.

"Our peptide is also derived from a protein which is produced naturally by the human body and appears to play a role as the body's own off-switch for inflammation. 

"It's been really great that Isis Innovation have worked with us over the last five years to ensure that these important early steps in reaching the potential of this discovery have happened. We are also delighted to be working with Rogne Bioscience."

Rogne's Chief Medical Officer, Karl Beutner, MD said: "All the biologic drugs that we currently use for treating conditions such as psoriasis work by dampening down inflammation all over the body, not just in the skin where the disease occurs. As a result they all have general immunosuppressive side-effects such as increases in number and severity of infections."

The peptides are derived from the plasma protein chemerin and work by reducing the production of inflammatory signaling proteins called cytokines which play a central role in the body's response to infection and injury. They are also implicated in the excessive immune responses underlying inflammatory diseases. The peptides inhibit activated antigen presenting cells by reducing the production of inflammatory cytokines including IL-12/23, TNFalpha, RANTES, IL-6 and IL-1beta.

Isis has granted Rogne an exclusive, world-wide licence to the associated patents.

The initial work in Professor Greaves' lab investigating inflammation was funded by the British Heart Foundation in the context of possible novel anti-inflammatory treatments for cardiovascular disease.  Professor Jeremy Pearson, Associate Medical Director at the Foundation, said: "We are delighted that the research we funded has now led to a potential new anti-inflammatory treatment for psoriasis."

Media enquiries:
Renate Krelle
Isis Innovation Ltd
T: +44(0)1865280867

Lena Wu
Rogne Bioscience, Inc.

About Isis Innovation

Isis Innovation is the research and technology commercialisation company of the University of Oxford. We provide access to technology from Oxford researchers through intellectual property licensing, spin-out company formation and material sales, and to academic expertise through Oxford University Consulting.

Isis is the highest university patent filer in the UK and is ranked 1st in the UK for university spin-outs, having created more than 100 new companies in 25 years. In the last financial year we completed 395 licenses and consulting agreements with clients in 21 countries. The Isis Enterprise innovation management consultancy works with university, government and industrial clients from offices around the world.

For updates on innovations from Oxford, follow Isis on LinkedIn and Twitter or subscribe at

About Rogne Bioscience

Rogne Bioscience is an early stage, San Francisco Bay area-based biotechnology company focused on bringing forward novel biological treatments for inflammatory diseases. Its first clinical program will target psoriasis. For more information, please visit

About the British Heart Foundation

The British Heart Foundation is a publicly funded research charity that supports over 50% of the UK's academic cardiovascular research.

PR 137/1

SOURCE Rogne Bioscience, Inc.; Isis Innovation Ltd
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
2. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
3. Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies
4. Oxford Finance Completes $271.4 Million Securitization Transaction
5. Oxford University Hospitals NHS Trust and the Bodleian Libraries Select ClinicalKey
6. Oxford Performance Materials and Biomet Microfixation Join Forces
7. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
8. Oxford BioMedica Announces Update from ARVO 2013
9. Oxford University Press to publish BioScience journal starting in 2014
10. Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors
11. HistoRx Licenses Melanoma Assay from Yale University
Post Your Comments:
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
(Date:6/23/2016)... FRANCISCO , June 22, 2016  Amgen (NASDAQ: ... sponsorship of the QB3@953 life sciences incubator ... human health. The shared laboratory space at QB3@953 was ... overcome a key obstacle for many early stage organizations ... part of the sponsorship, Amgen launched two "Amgen Golden ...
Breaking Biology Technology:
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/26/2016)... and LONDON , ... Finacle, part of EdgeVerve Systems, a product subsidiary ... Onegini today announced a partnership to integrate the ...      (Logo: ) ... provide their customers enhanced security to access and ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
Breaking Biology News(10 mins):